Compare SSII & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSII | CSTL |
|---|---|---|
| Founded | N/A | 2007 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | N/A | 2019 |
| Metric | SSII | CSTL |
|---|---|---|
| Price | $6.01 | $40.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $46.00 |
| AVG Volume (30 Days) | 69.4K | ★ 333.2K |
| Earning Date | 02-14-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $36,066,457.00 | ★ $343,530,000.00 |
| Revenue This Year | N/A | $2.54 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 158.36 | 10.15 |
| 52 Week Low | $3.02 | $14.59 |
| 52 Week High | $22.42 | $42.18 |
| Indicator | SSII | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 57.91 |
| Support Level | $5.34 | $38.73 |
| Resistance Level | $6.05 | $41.60 |
| Average True Range (ATR) | 0.46 | 1.58 |
| MACD | 0.06 | -0.12 |
| Stochastic Oscillator | 87.05 | 62.75 |
SS Innovations International Inc is a commercial-stage surgical robotics company focused on transforming patient lives by democratizing access to advanced surgical robotics technologies. The company designs, manufactures, and markets an advanced, next-generation, and affordable surgical robotic system called the SSi Mantra, and the instruments and accessories used with SSi Mantra to perform a wide range of soft-tissue, robotically assisted surgeries. The company earns the majority of its revenue from India.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.